Formulary Search - PAD Formulary

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results

Records returned : 37.

Guideline Profile : Inflammatory bowel disease
Brand names include : Humira, Hyrimoz, Amgevita, Hulio, Imraldi, Mylan, Yuflyma, Idacio, Jyseleca, Simponi, Remicade, Inflectra, Remsima, Flixabi, Zessly, Omvoh, Zeposia, Xeljanz, Rinvoq, Stelara, Entyvio, Entyvio SC, Skyriza,
Guideline Profile : Ulcerative colitis
Mycophenolate mofetil - Gastroenterology indications
Brand names include : Arzip, CellCept, Myfortic, Myfenax, Ceptava
Adalimumab - Inflammatory bowel disease
Brand names include : Humira, Amgevita, Imraldi, Hulio, Hyrimoz, Mylan, Yuflyma, Idacio
Allopurinol - Inflammatory bowel disease
Azathioprine - Inflammatory bowel disease
Brand names include : Imuran, Jayempi
Balsalazide sodium - Inflammatory bowel disease
Brand names include : Colazide
Budesonide - Inflammatory bowel disease
Brand names include : Budenofalk
Ciclosporin - Inflammatory bowel disease
Brand names include : Capimune, Capsorin, Deximune, Neoral, Sandimmun, Vanquoral
Darvadstrocel - Inflammatory bowel disease
Brand names include : Alofisel
Etrasimod - Inflammatory bowel disease
Brand names include : Velsipity
Filgotinib - Inflammatory bowel disease
Brand names include : Jyseleca
Golimumab - Inflammatory bowel disease
Brand names include : Simponi
Guidelines - Inflammatory bowel disease
Infliximab - Inflammatory bowel disease
Brand names include : Remicade, Inflectra, Remsima, Flixabi, Zessly
Mercaptopurine - Inflammatory bowel disease
Brand names include : Puri-Nethol
Mesalazine - Inflammatory bowel disease
Brand names include : Octasa, Salofalk Granules, Pentasa, Mezavant, Zintasa
Methotrexate - Inflammatory bowel disease
Brand names include : Metoject, Maxtrex, Methofill, Nordimet, Zlatal
Mirikizumab - Inflammatory bowel disease
Brand names include : Omvoh
Olsalazine sodium - Inflammatory bowel disease
Ozanimod - Inflammatory bowel disease
Brand names include : Zeposia
Prednisolone - Inflammatory bowel disease
Brand names include : Predfoam
Prednisolone (Oral) - Inflammatory bowel disease
Brand names include :
Risankizumab - Inflammatory bowel disease
Brand names include : Skyrizi
Sulfasalazine - Inflammatory bowel disease
Brand names include : Salazopyrin EN, sulazine
Tofacitinib - Inflammatory bowel disease
Brand names include : Xeljanz
Upadacitinib - Inflammatory bowel disease
Brand names include : Rinvoq
Ustekinumab - Inflammatory bowel disease
Brand names include : Stelara
Vedolizumab - Inflammatory bowel disease
Brand names include : Entyvio, Entyvio SC
Infliximab - Inflammatory bowel disease - paediatric use
Brand names include : Inflectra, Remicade, Remsima
Asacol - Ulcerative colitis
Hydrocortisone Foam enema - Ulcerative colitis
Brand names include : Colifoam
Adalimumab - Ulcerative colitis - moderately to severely active
Brand names include : Humira, Hyrimoz, Amgevita, Hulio, Imraldi, Mylan, Yuflyma, Idacio
Infliximab - Ulcerative colitis - moderately to severely active
Brand names include : Remicade, Inflectra, Remsima, Flixabi, Zessly
Upadacitinib - Ulcerative colitis - moderately to severely active
Brand names include : Rinvoq
Ustekinumab - Ulcerative colitis - moderately to severely active
Brand names include : Stelara
Vedolizumab - Ulcerative colitis - moderately to severely active
Brand names include : Entyvio, Entyvio SC

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1

Non formulary

NFD2

Not assessed for formulary status. Apply to APC / DTC before use.

Controlled drug. Prescribing and/or storage requirements may apply

Restrictions apply

Safety Alert

Unlicensed - no UK marketing license in place

Off-label use. Not licensed for this indication.

NHSE

Treatment commissioned by NHS England

CDF

ICB

Treatment commissioned by the ICB

BlueTeq

BlueTeq form to be completed

NICE

Traffic Light Status Key

Red

Specialist ONLY drugs - treatment initiated and continued by specialist clinicians

Amber

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement

Green

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.

Black

Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.

Amber Star

Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

Green (see narrative)

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.

Non Formulary

Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)

See Below

Please add a description.

N/A

Please add a description.

Blue

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

Green - Black

Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.

See narrative

See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)

Do not initiate in new patients

These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)